Fitch Affirms Agilent Debt Ratings; Revises Outlook to Stable | GenomeWeb

NEW YORK (GenomeWeb News) – Fitch Ratings today affirmed its long-term rating on Agilent Technologies' debt at 'BBB+' and revised its outlook to stable from positive, following Agilent's announcement earlier in the day that it would split into two separate, publicly traded firms.

Agilent said that the life sciences and diagnostics business, which also includes its genomics and applied markets products, will retain the Agilent name. It has annual revenues of around $3.9 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.